Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson 1Q

Pharma sales down 7% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

1Q Revenues: $17.4 billion (-4%)

1Q Earnings: $4.3 billion (-9%)

Comments: Pharmaceutical sales were $7.7 billion, down 7% in the quarter. RISPERDAL CONSTA sales were down 18% to $254 million. VELCADE sales were down 17% to $339 million. OLYSIO/ SOVRIAD sales were down 34% to $234 million, due to generic completion. REMICADE sales were $1.6 billion, down 0.6%. STELARA sales were $549 million, up 20%. CONCERTA sales were $224 million, up 49%. SUSTENNA/XEPLION sales were $441 million up 10%. During the quarter, the FDA approved IMBRUVICA (ibrutinib) for the treatment of Waldenström’s Macroglobulinemia and for PREZCOBIX (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of HIV-1. Worldwide Consumer sales were $3.4 billion in the quarter, down 5%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters